Comments
rlebherz wrote: Alf, Interesting article. I think the Cloud services and cloud infrastructure lines are a bit blurred, but I agree with most of what you are saying. Dont underestimate the SLA's role in accountability. For companies that have dynamic requirements and no down time can be afforded, make sure you have very tight SLAs. For example, OpSource provides a 100% SLA in the cloud and 100%SLA around production application environments. Now 100% is ideally perfect, it comes down to accountability, yo...
Cloud Expo on Google News

SYS-CON.TV

2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Click For 2008 West
Event Webcasts
Excellent Stem Cell Mobilization and Safety Profile for TG-0054

TAIPEI, Taiwan, Sept. 28 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated.

The trial was a randomized, double-blind, placebo-controlled, single intravenous dose study including 64 healthy volunteers in US, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of TG-0054 in 8 cohorts. The mobilized stem and progenitor cells peaked at 4-6 hours following one single intravenous dose.

"We are greatly encouraged by the phase 1 study results which indicates that TG-0054 has the potential to be used alone, not in combination with G- CSF, for allogenic or autologous stem cell transplantation in cancer patients. This should greatly reduce the hospital and other associated cost for such a procedure. Importantly, the activity and safety profile in the phase 1 study will support our future development of TG-0054 in chemosensitization and tissue ischemia, including myocardial infarction, stroke and severe intermittent claudication. Our preclinical animal disease models and the phase 1 study results lend strong support to clinical development for these clinical indications," said Dr. Ming-Chu Hsu, Chairman & CEO of TaiGen.

About TaiGen Biotechnology

TaiGen Biotechnology ( http://www.taigenbiotech.com/ ) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company has a full capacity in discovery research and clinical development in China/Taiwan/US. Its current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market. In addition to TG-0054, Nemonoxacin, a novel broad-spectrum non-fluorinated quinolone with anti-MRSA activity and in- licensed from P&G Pharmaceuticals, achieved non-inferiority in clinical cure rate and safety profile compared with Levofloxacin in its Phase II CAP trial. The company has completed a second phase II study in diabetic foot infection to demonstrate Nemonoxacin's anti-MRSA activity with once-a-day oral dosing. TaiGen is seeking Nemonoxacin licensees for the US, EU and Japan markets. TaiGen also has HCV protease inhibitors in advanced preclinical programs to treat chronic hepatitis C infection.

    TaiGen Contact

     Dr. Stephen Ip, Sr. VP Global Business Development
     Tel:   +886-2-2790-1861
     Email: Stephenip@taigenbiotech.com.tw

SOURCE TaiGen Biotechnology Co., Ltd.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
This article looks at the basic interoperability requirements when communicating with the Cloud, and in particular at techniques and standards used to express and enforce wire-level contracts between communicating parties, as these parties are increasingly also contracting partie...
In the interest of selling more widgetry to more people, IBM has transformed one of its mainframes into what it calls Blue Insight, a private cloud packed initially with a petabyte of structured and unstructured data that 200,000 of its sales, product development and manufacturin...
RightScale, the cloud manager, plans to support Windows Azure and let customers deploy RightScale-managed applications and take advantage of Azure’s particular properties. It said it would support Azure infrastructure-level services through its new Service Management API like it ...
Joyent, whose customers include ABC Disney, CNN, The Gap, Facebook, LinkedIn and Yahoo, developed its own custom OS and data center virtualization technology, which creates a multi-tenant cloud. It’s supposed to deliver more than 70% utilization, which is eight times more than in...
Salesforce.com is going the way of Facebook and Twitter with a reportedly secure private social networking application called Chatter that companies are supposed to use internally so their people can “collaborate” in real-time, but potentially the techzoid equivalent of the old-f...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News